Ever since the introduction of the concept of gestational diabetes mellitus, there has been controversy about the importance of this condition and the appropriateness of screening for it. Societies and associations such as the American College of Obstetricians and Gynecologists, the American Diabetes Association (ADA), the Canadian Diabetes Association and the Fourth International Workshop-Conference on Gestational Diabetes Mellitus have recommended either universal or selective screening. These recommendations are based on the premise that identification and treatment of gestational diabetes will avert some of the adverse outcomes that have been associated with this condition, such as pregnancy-induced hypertension, macrosomia (potentially associated with fetal birth trauma), perinatal mortality and neonatal metabolic disorders. Other bodies, such as the Canadian Task Force on the Periodic Health Examination and the Society of Obstetricians and Gynecologists of Canada, have taken a more cautious approach, noting that there is insufficient scientific data to suggest that identification and treatment of gestational diabetes result in better maternal and neonatal outcomes. Indeed, there is evidence that identification of gestational diabetes may result in unfavourable maternal and neonatal outcomes. Hunter and Keirse, in their contribution to Effective Care in Pregnancy and Childbirth, concluded that “except for research purposes all forms of glucose tolerance testing should be stopped.” Thus, it is important that studies be conducted to determine whether identification and treatment of gestational diabetes is associated with improvement in maternal and neonatal outcomes.

In this issue of CMAJ (page 403), Christian Ouzilleau and colleagues report their retrospective study of 300 pregnant women who had abnormal results on screening with a randomly administered 50-g glucose load and who subsequently underwent a follow-up 3-hour, 75-g oral glucose tolerance test (OGTT). These women received minimal or no therapeutic interventions. They were compared with a group of 300 pregnant women whose results on the initial screening were normal. The incidence of macrosomia was similar in the 2 groups.

The authors went on to look at the correlation between birth weight and 3 separate sets of plasma glucose values: on screening (1 hour after a 50-g glucose load), while fasting and 2 hours after a 75-g load. In each of these 3 analyses, progressively increasing plasma glucose values were associated with a progressive increase in birth weight, although the correlation was weak in each case. The authors also performed multiple regression analysis to see if plasma glucose values while fasting and 2 hours after the 75-g glucose load remained independent predictors of birth weight. In both cases, plasma glucose remained an independent predictor, but the correlation was even weaker than in the initial analyses. The multiple regression analysis also showed that prepregnancy weight, weight gain during pregnancy and parity had a significant positive association with birth weight. Conversely, smoking had a significant but negative correlation with birth weight. Smoking, prepregnancy weight, weight gain during pregnancy and parity had higher correlations with birth weight than either fasting plasma glucose or plasma glucose 2 hours after a 75-g load. These results confirm the work of others, demonstrating that factors other than gestational diabetes are often associated with an increased rate of macrosomia.

The ability of plasma glucose (on screening with a 50-g load, while fasting and 2 hours after a 75-g load) to predict birth weight at or above the 90% percentile was investigated by analysis of receiver operating characteristic curves. According to Ouzilleau and colleagues, the predictive value of these 3 plasma glucose variables was “mediocre” and demonstrated “modest risk stratification performance.” The paper does not mention the proportion of patients who were actually diagnosed with gestational diabetes at the time of their pregnancies. It would appear that the proportion was less than 12.7% or 13.3% (the proportions estimated retrospectively on the basis of ADA criteria, as shown in Table 2 of the paper), given that the diagnostic thresholds used by the institution where the women underwent screening (which were based on National Diabetes Data Group criteria) were higher than the ADA thresholds. Therefore, it appears that about 90% of the study population had no evidence of gestational diabetes and, for that reason, a high rate of macrosomia should not have been anticipated. Thus, in their conclusions, the investigators are running a risk of type II error.

The results of this carefully conducted study suggest that screening for gestational diabetes in an effort to pre-
Each of the following approaches is acceptable.

a. Routine screening of women at 24–28 weeks of gestation may be recommended with the 50-g glucose challenge test (GCT), using a threshold of 7.8 mmol/L (140 mg/dL), except in those women who fulfill the criteria for low risk, which includes the following:

- Maternal age < 25 years
- Caucasian or member of other ethnic group with low prevalence of diabetes
- Pregnant body mass index (BMI) ≤ 27
- No previous history of GDM or glucose intolerance
- No family history of diabetes in first-degree relative
- No history of GDM-associated adverse pregnancy outcomes

The diagnostic test can be the 100-g oral glucose tolerance test (OGTT) as recommended by ACOG, or the 75-g OGTT, according to the American Diabetes Association (ADA) criteria. Use of the World Health Organization (WHO) criteria will approximately double the number of women diagnosed with GDM without an apparent clinical benefit.

b. A small but significant number of Canadian obstetricians and centres have a policy of non-screening for GDM. Until evidence is available from large RCTs that shows a clear benefit from screening for glucose intolerance in pregnancy, the option of not screening for GDM is considered acceptable. Conversely, there are no compelling data to stop screening when it is practiced.

c. The clinician should consider the recommendation of the Fourth International Workshop-Conference that women considered at high risk for GDM should undergo a diagnostic test as early in pregnancy as possible and that testing should be repeated at 24–28 weeks if initial results are negative.

d. If GDM is diagnosed, glucose tolerance should be reassessed with a 75-g OGTT 6–12 weeks postpartum in order to identify women with persistent glucose intolerance.

Box 1: Summary of Society of Obstetricians and Gynaecologists of Canada recommendations for screening for gestational diabetes mellitus (GDM)

A single approach of testing for GDM cannot be recommended at the present as there is not enough evidence-based data proving the beneficial effect of a large screening program.

Each of the following approaches is acceptable.

This study underscores the controversy at the heart of the debate over the importance, or even the existence, of gestational diabetes. Some physicians in Canada do not believe that this condition exists, and others feel that its importance is so low that screening is not justified. Many researchers, in studies like this one, are trying to shed light on this subject, but the controversy will only end once a robust, randomized, double-blind trial is conducted to demonstrate whether identification and management of gestational diabetes is associated with significant improvement in neonatal or maternal outcome. Unfortunately, no such study is yet under way.

While waiting for the results of such a trial, it would be reasonable to follow the SOGC guidelines published in November 2002 (see Box 1).

From the Department of Obstetrics and Maternal-Fetal Medicine, Mount Sinai Hospital, Toronto, Ont.

Competing interests: None declared.

References


5. O’Sullivan JB, Charles D, Mahan CM, Dandrow RV. Gestational diabetes


---

**Commentary**

**Correspondence to:** Dr. Mathew Sermer, Department of Obstetrics and Maternal-Fetal Medicine, Mount Sinai Hospital, 1207-600 University Ave., Toronto ON M5G 1X5; fax 416.586-4494; msermer@mtsina.on.ca

---

**O How do you find the information you need to make the best health care choices?**

**A Consult**

**The Cochrane Library**

Now updated quarterly, this electronic library is designed to give you the evidence you need for informed health care decision-making. The Cochrane Library now contains 6 databases:

- The Cochrane Database of Systematic Reviews
- The Database of Abstracts of Reviews of Effectiveness
- The Cochrane Controlled Trials Register
- The Cochrane Review Methodology Database
- The Health Technology Assessment Database
- The NHS Economic Evaluation Database

$323.95/CMA members, $359.95/nonmembers. All orders must be prepaid. Please add 7% GST/HST (as applicable), 8% PST (Ontario residents only) and $4 shipping/handling. Please contact CMA Member Service Centre for network prices. Available on CD-ROM or the Internet.

CMA Member Service Centre
tel 888 855-2555 or 613 731-8610 x2307
cmamsc@cma.ca